Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What are the Key Projections for the CAGR of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market From 2025 to 2034?
The market size for the poly ADP-ribose polymerase (PARP) inhibitor has expanded significantly in the past few years. There’s a projected growth from $8.39 billion in 2024 to $9.41 billion in 2025, yielding a compound annual growth rate (CAGR) of 12.1%. The historical growth of this market is primarily due to factors such as clinical studies, regulatory greenlights, competitive market landscape, drug mixtures, and patient representation.
It is predicted that the poly ADP-ribose polymerase (PARP) inhibitor market will experience a significant increase in size over the coming years. By 2029, it’s expected to reach $14.67 billion, with a compound annual growth rate (CAGR) of 11.7%. This growth during the projected period is due to factors such as expanded indications, personalized healthcare, development of biomarkers, health economic factors, and emerging markets. Key trends predicted for the forecast period include precision medicine, advances in immunotherapy, targeted therapeutic strategies, the application of artificial intelligence in drug discovery, and a patient-oriented approach in healthcare.
How Are the key drivers expanding the growth of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The rising incidence of ovarian cancer, which is a malignant tumor that manifests in one or both ovaries in women, is anticipated to boost the progress of the poly ADP-ribose polymerase (PARP) inhibitor market in future. The ovaries, a crucial part of the female reproductive system, are responsible for egg production and the creation of female hormones. Reasons behind the growth of ovarian cancer include genetic predisposition, an older demographic, environmental factors and hormonal imbalance. Poly ADP-Ribose Polymerase (PARP) Inhibitors are utilized in treating ovarian cancer by specifically targeting DNA repair mechanisms, immensely effective in patients with BRCA mutations. This leads to synthetic lethality and an increase in tumor cell death. For example, The World Ovarian Cancer Coalition, a non-profit organization based in Canada, forecasted in February 2024 that the number of women dying every year due to ovarian cancer is projected to escalate to 350,956, a jump of nearly 70% from 2022. Consequently, the escalating incidence of ovarian cancer is propelling the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.
Explore Comprehensive Insights Into The Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
What Are the Key Industry Players Leading the Charge in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market’s Growth?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are:
• Pfizer Inc._x000D_
• Johnson & Johnson Services Inc._x000D_
• AbbVie Inc._x000D_
• Bayer AG_x000D_
• Novartis AG_x000D_
How Are Market Trends and Shifts Impacting the Growth Trajectory of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
Leading corporations in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on the creation of generic PARP inhibitors, aiming to provide customised treatment methods for cancer patients with unique genetic mutations. Generic PARP inhibitors are medicinal drugs that halt the function of the poly ADP-ribose polymerase (PARP) enzyme. As an illustration, Zydus Lifesciences Limited, a pharmaceutical organisation from India, introduced Olaparib, a PARP inhibitor under the IBYRA brand in March 2024, with the goal of increasing access to advanced cancer therapies. The IBYRA medical drug targets specific genetic mutations present in cancers like breast, ovarian, prostate, and pancreatic, thus providing a personalised and effective treatment strategy. This drug exhibits high efficacy especially in patients with HRD-positive or BRACA mutations and aids in slowing down the disease’s progression.
Secure Your Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report Now for Fast and Efficient Delivery!
What Are the Major Categories and Their Growth Dynamics in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
What Regions Are Influencing the Dynamics of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Definition of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Impacting Future Growth?
Poly ADP-ribose polymerase (PARP) inhibitors are a class of pharmacological inhibitors that block the enzyme PARP, which is involved in deoxyribonucleic acid (DNA) repair. These inhibitors treat cancers with defects in other DNA repair pathways, preventing cancer cells from repairing damaged DNA and leading to their death.
Browse Through More Similar Reports By The Business Research Company:
Interleukin Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024
HER2 Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
